Dr. Strosberg was lead investigator for the NETTER-1 trial—sponsored by Novartis’ Advanced Accelerator Applications.  He says “There are very few effective treatment options for patients with inoperable, advanced GEP-NETs who are progressive on somatostatin analogues....